Lataa...
“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
PURPOSE: PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in patients with heart failure and reduced ejection fraction (HF-REF). How widely applicable sacubitril/valsartan treatment is in unselected patients with HF-REF is not known. We examined eligibility of patients...
Tallennettuna:
| Julkaisussa: | Cardiovasc Drugs Ther |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer US
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6538576/ https://ncbi.nlm.nih.gov/pubmed/30903545 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06873-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|